The Question Worth Asking
You have received a glioblastoma diagnosis. Or the tumor has returned. In the days that follow—juggling shock, appointments, and uncertainty—a question surfaces: Is there something more? Is there information my team may not have?
This question doesn't mean you distrust your doctors. It's one of the most important questions a glioblastoma patient or caregiver can ask.
Every year, families across the world seek additional expert review beyond their local hospital. They do this because glioblastoma is one of the most complex tumors in medicine. Understanding its molecular details may open conversations that wouldn't otherwise happen.
Why No Two Glioblastomas Are the Same
On the surface, every glioblastoma diagnosis looks similar: grade IV, IDH-wildtype, aggressive. The treatment path—surgery, radiation, and chemotherapy—is largely the same for everyone. But beneath that shared label, each tumor is different. A unique combination of mutations, gene expression patterns, signaling pathways, and molecular vulnerabilities distinguishes one patient's tumor from another's.
The American Brain Tumor Association notes that glioblastoma is the most common primary malignant brain tumor in adults and one of the most aggressive. Its molecular characteristics vary widely even among patients with the same diagnosis. This biological difference matters. It shapes how a tumor behaves, how it responds to treatment, and what treatment targets might exist beyond standard care.
What Standard Testing Misses
Most hospital-based molecular testing covers what is clinically required: IDH mutation status, MGMT promoter methylation, and sometimes EGFR amplification or TERT promoter status. These are meaningful markers. MGMT methylation shows potential response to chemotherapy, as explained by the National Brain Tumor Society.
But standard panels cover only part of the molecular information relevant to a tumor. A comprehensive review of molecular testing in gliomas published in PMC shows that the 2021 WHO classification expanded the role of molecular and genetic data in tumor definition and treatment guidance—a shift many standard testing protocols haven't adopted yet.
Whole Exome Sequencing (WES) analyzes the protein-coding regions of the entire genome—thousands of genes at once instead of a fixed panel. Research on personalizing glioblastoma treatment with whole exome sequencing found that this approach uncovers individualized treatment options standard testing misses. RNA Sequencing adds another dimension, showing which genes are active in the tumor at the time of testing—revealing biology as it happens, not just the static genetic code.
Tumor heterogeneity adds another layer of complexity. Research on glioblastoma tumor heterogeneity shows that different parts of the same tumor can carry different molecular profiles. A single biopsy sample may not show the full picture. An expert review combining imaging, pathology, and sequencing together may surface important questions for your treating team.
For details on what specific molecular markers mean in your glioblastoma report, see our guide to interpreting your glioblastoma molecular report.
What Remote Molecular Assessment Includes
Expert oncology review no longer requires travel. Digital pathology platforms, cloud-based genomic tools, and secure file-sharing systems let a specialist in one country review a case for a patient in another with the same depth as an in-person consultation.
A remote precision oncology assessment can include:
- MRI scan review. Brain MRI files in DICOM format can be uploaded securely and reviewed by a neuro-oncology expert. Tumor location, extent of resection, post-operative changes, and signs of progression can all be assessed remotely.
- Pathology and histopathology analysis. Reports describing the tumor tissue sample can be reviewed for completeness, accuracy under 2021 WHO criteria, and any gaps in the initial workup.
- Molecular testing interpretation. Existing sequencing results, biomarker panels, and genetic data can be analyzed by specialists with deep expertise in neuro-oncology molecular medicine.
- Whole Exome Sequencing and RNA Sequencing. When tissue material is available, additional sequencing not done locally can be coordinated remotely with expert interpretation provided when complete.
- Drug Sensitivity Analysis. Advanced analysis of how tumor biology may interact with specific agents—including repurposed compounds not standard in glioblastoma care—can be part of the assessment.
- CSF Liquid Biopsy Intelligence. Analysis of circulating tumor DNA in cerebrospinal fluid provides real-time insight into tumor activity that imaging alone cannot show. For more on how this works, see our article on liquid biopsy monitoring in glioblastoma.
- Virtual expert consultation. A secure video consultation lets patients, caregivers, and precision oncology specialists discuss findings directly—exploring what the molecular data means for conversations with the local treating team.
Why Expertise Matters More Than Location
Patients and families in the UK, Australia, Canada, the UAE, and across Europe aren't necessarily looking for a different hospital. They're looking for a different depth of knowledge—specifically, molecular expertise that may not be available at every neuro-oncology center, regardless of how strong that center is at standard care.
This difference matters. Standard-of-care glioblastoma treatment exists in all major cities. What patients increasingly want is something more: a precision-level analysis of their tumor's biology, interpreted by someone whose focus is exactly that question.
The National Brain Tumor Society notes that patients treated at specialized, high-volume centers benefit from expertise—particularly for rare and complex tumors—that isn't everywhere available. Remote review makes that expertise accessible without relocation or travel.
A patient in Birmingham can submit MRI scans and pathology reports online. A caregiver in New Zealand can join a video consultation for a parent. A family in Dubai can have their loved one's molecular testing reviewed by a specialist focused on glioblastoma biology. Initial reports can be uploaded, consultations held, and findings discussed—all from home.
What Records to Gather Before Expert Review
A remote review is only as thorough as the materials provided. Before contacting a precision oncology service, gather these documents:
- Pathology Report – the document from your neurosurgeon or pathologist describing what was found in the tumor tissue sample
- Histopathology Report – the detailed microscopic analysis, including immunohistochemistry findings
- MRI Brain Reports – both the radiologist's written report and the actual imaging files in DICOM format if possible
- Surgical Notes – the operative report from any craniotomy, biopsy, or debulking procedure
- Molecular Testing Results – all genetic or biomarker panel results, including IDH status, MGMT methylation, EGFR, TERT, and any other markers tested
- Current Treatment Plan – the protocol from your oncology team, including chemotherapy, radiation schedule, and any devices like Tumor Treating Fields
- Previous Treatment History – a summary of all prior treatments, agents used, and clinical response at each stage
Many families find that gathering these records sharpens their own understanding. Questions emerge in the process. Questions raised early lead to better-informed decisions at every step.
For patients with a recent initial diagnosis, our first-month checklist after a high-grade glioma diagnosis provides a guide to what to gather and what to ask during the critical early weeks.
Common Mistakes After Diagnosis
The weeks after a glioblastoma diagnosis move fast. Most families make at least one of these missteps—not from carelessness, but from the pace of events:
- Accepting a limited molecular workup. If your report covers only IDH and MGMT, ask whether broader sequencing is worth considering for your case.
- Waiting until recurrence to seek additional expertise. Many patients pursue precision review only after standard treatment hasn't worked. Earlier review may surface relevant information while more treatment options are available.
- Treating expert review as disloyalty. Seeking a precision oncology assessment isn't a criticism of your local oncologist. For complex diagnoses, it's considered sound practice and is actively encouraged by major brain tumor organizations.
- Submitting incomplete records. Partial records produce partial reviews. A meaningful analysis needs MRI imaging, pathology, surgical notes, and molecular data together, not separate pieces.
- Assuming travel is required. Many families don't know remote review services exist. Secure file submission and video consultations eliminate any geographic requirement.
Questions to Ask Your Oncology Team
If you're pursuing additional expert input alongside your local treatment, these questions can help structure conversations with your oncologist:
- Has my tumor been classified according to the updated 2021 WHO criteria for central nervous system tumors?
- Which molecular tests were completed, and were any skipped—and if so, why?
- Is Whole Exome Sequencing or RNA Sequencing appropriate or available for my case?
- How was MGMT status confirmed—through methylation-specific PCR, pyrosequencing, or another method?
- Are there clinical trials my tumor's molecular profile might qualify me for?
- How would additional molecular data change or refine the current treatment strategy?
These questions aren't confrontational. They show you're committed to fully informed decision-making. For details on what each major molecular test reveals and how it shapes treatment choices, see our guide to molecular tests for newly diagnosed glioblastoma.
When to Talk to Your Doctor
If you're considering a remote molecular assessment or virtual expert consultation, discuss this with your oncologist early. The best outcomes come from coordination between expert perspectives—not from separate tracks that don't communicate. A precision oncology review works alongside your existing care team, not instead of it.
If you're at recurrence and weighing next-line options, an updated molecular analysis may be particularly relevant. Glioblastoma tumors can change over the course of treatment. The biology at recurrence may differ from the biology at initial diagnosis—and a current molecular snapshot may support more targeted conversations about treatment approaches worth exploring.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.